drugset / Trial / NCT05116475
Evaluation of dAroLutamide Addition to anDrogen Deprivation Therapy and radIatioN Therapy in Newly Diagnosed Prostate Cancer With Pelvic Lymph Nodes Metastases
Phase 3
Recruiting
152 enrolled
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Bayer · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
Prospective, multicenter, comparative, randomized placebo-controlled Phase III trial - patients with hormone-naïve prostate cancer and pelvic lymph nodes metastases
Timeline
- Start
- 2022-08-30
- Primary completion
- 2026-02
- Completion
- 2027-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Darolutamide | Other / unclassified | 300 mg | Oral |